Fate

FATE NASDAQ
21.37
-1.13
-5.02%
After Hours: 21.37 0 0.00% 17:04 07/19 EDT
Open
22.50
Prev Close
22.50
High
22.50
Low
21.34
Volume
584.67K
Avg Vol (3M)
790.14K
52 Week High
22.82
52 Week Low
8.64
% Turnover
0.90%
Market Cap
1.39B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Fate FATE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
MORE >

Recently

Name
Price
%Change